Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis
- PMID: 22103889
- DOI: 10.1111/j.1542-4758.2011.00644.x
Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis
Abstract
The response to erythropoietin (EPO) treatment varies considerably in individual patients on chronic hemodialysis. The EPO resistance index (ERI) has been considered useful to assess the EPO resistance and can be easily calculated in the clinic. The aim of this study was to investigate the association between ERI and left ventricular mass (LVM) and function and to determine whether ERI was associated with cardiovascular events in patients on hemodialysis. This study was designed prospectively. Clinical, laboratory, and echocardiographic variables were assessed in 72 patients on hemodialysis. The ERI was determined as the weekly weight-adjusted dose of EPO (U/kg/week) divided by hemoglobin concentration (g/dL). Patients were divided into three groups by tertiles of ERI. Patients with higher tertiles of ERI had a higher LVM index and lower LV ejection fraction compared with those with lower tertiles of ERI (P = 0.019 and P = 0.030, respectively). The median follow-up period was 53 months. The Kaplan-Meier plot showed increased frequency of cardiovascular events in patients with higher tertiles of ERI, compared with those with lower tertiles of ERI (P = 0.011, log-rank test). The multivariate Cox proportional hazard models showed that the ERI was the significant independent predictor of cardiovascular events (HR 3.00, 95% CI, 1.04-8.62, P = 0.042). Our data show that ERI was related with LVM index, LV systolic function and cardiovascular events in patients with hemodialysis. By monitoring of ERI, early identification of the EPO resistance may be helpful to predict the cardiovascular risk in hemodialysis patients.
Similar articles
-
Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status.Blood Purif. 2004;22(5):423-7. doi: 10.1159/000080234. Epub 2004 Aug 13. Blood Purif. 2004. PMID: 15316197
-
Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.Nefrologia. 2012 May 14;32(3):343-52. doi: 10.3265/Nefrologia.pre2012.Jan.11111. Epub 2012 Apr 17. Nefrologia. 2012. PMID: 22535158 English, Spanish.
-
Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.Nephrol Dial Transplant. 1995;10(8):1398-404. Nephrol Dial Transplant. 1995. PMID: 8538932
-
High-intensity hemodialysis: the wave of the future?Int J Artif Organs. 2008 Mar;31(3):201-12. doi: 10.1177/039139880803100303. Int J Artif Organs. 2008. PMID: 18373313 Review.
-
Adjustment of drug dosage to hemodialysis patients.Adv Exp Med Biol. 1989;260:93-103. doi: 10.1007/978-1-4684-5718-6_10. Adv Exp Med Biol. 1989. PMID: 2696374 Review. No abstract available.
Cited by
-
Erythropoietin resistance among pediatric patients on chronic hemodialysis: A cross-sectional study.Pediatr Nephrol. 2025 Apr 28. doi: 10.1007/s00467-025-06776-4. Online ahead of print. Pediatr Nephrol. 2025. PMID: 40293460
-
V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.J Biomed Sci. 2017 Jul 11;24(1):43. doi: 10.1186/s12929-017-0349-5. J Biomed Sci. 2017. PMID: 28697735 Free PMC article. Clinical Trial.
-
The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure.Hemodial Int. 2016 Jul;20(3):392-8. doi: 10.1111/hdi.12407. Epub 2016 Feb 3. Hemodial Int. 2016. PMID: 26843352 Free PMC article.
-
Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.Int Urol Nephrol. 2014 Jan;46(1):151-9. doi: 10.1007/s11255-013-0494-z. Epub 2013 Jun 27. Int Urol Nephrol. 2014. PMID: 23807369
-
Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.Pediatr Nephrol. 2018 Nov;33(11):2123-2129. doi: 10.1007/s00467-018-4016-1. Epub 2018 Jul 20. Pediatr Nephrol. 2018. PMID: 30030607
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials